KPV
KPV is a three-amino-acid peptide (lysine, proline, valine) from the end of the hormone alpha-MSH, studied in cells and mice but never tested in people.
US regulatory status
Not approved for human use in the US
KPV is not approved by the FDA for any use. As of April 2026 its nomination had been withdrawn from the FDA’s Category 2 safety-risk list, which notes the FDA found no human exposure data by any route. In July 2026 an FDA advisory committee narrowly voted, against FDA staff advice, to recommend adding it to the 503A bulks list; the vote is not binding, and as of October 16, 2026 no rule had been published.
At a glance
- Also known as
- Lys-Pro-Val, Lysine-proline-valine, KPV peptide, KPV acetate, Alpha-MSH (11-13)
- Supplied as
- Freeze-dried powder, mixed before use
- Research
- Animal or lab studies only
- US status
- US status: Not approvedchecked
What the research shows
Evidence grade
Animal or lab studies only
Studied in cells or animals, not properly in people. Animal results may not apply to humans.
The main study is from 2008. In human gut-lining cells and immune T cells grown in the lab, tiny (nanomolar) amounts of KPV blocked two inflammation pathways, NF-κB and MAP kinase. The cells took KPV in through a transporter called PepT1. In mice, KPV added to drinking water reduced chemically induced colitis. The FDA’s 2026 review, which looked at KPV for its nominated uses of wound healing and inflammatory conditions, found no study in which KPV was given to people, by any route. Websites promote KPV for inflammation, wound healing, skin health, nerve damage and stroke; none of those uses has been tested in humans.
How we grade evidence
Strong human evidence
Consistent results from large randomized controlled trials in people.
Limited human evidence
Some studies in people, but they are small, short, early-phase or uncontrolled.
Mixed evidence
Studies in people disagree, or strong evidence for one use sits beside weak evidence for another.
Animal or lab studies only · this page
Studied in cells or animals, not properly in people. Animal results may not apply to humans.
The grade describes how much research exists and in whom. It is not a judgment that a compound works or is safe.
Side effects and safety
Safety in humans is unknown, because KPV has never been studied in people. The FDA said it is particularly concerned about this lack of human data, including the lack of information to assess immune reactions or clumping (aggregation) of KPV, and concluded that potential safety risks are unknown. Its adverse event database had no KPV reports through December 3, 2025, a second FDA database had no cases where KPV was taken, and the medical literature had no adverse event cases. With no human studies, no reports is not the same as safe. KPV also has no official drug standard (USP monograph).
Vial math
Pre-filled calculators turn your vial, water and prescribed dose into syringe units.
Pre-filled for your vial size
This is arithmetic, not medical advice. Confirm with your prescriber or pharmacist.
Questions people ask
What are KPV peptides?
KPV is a single tiny peptide of three amino acids: lysine (K), proline (P) and valine (V). It is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It is sold as KPV or as KPV acetate; the FDA treats these as different ingredients and reviewed both. Online it is promoted in oral, injectable, topical and nasal spray forms, alone or mixed with other ingredients.
What are the benefits of KPV?
None have been shown in people. In lab-grown human gut and immune cells, KPV dampened inflammation signals, and in mice it reduced colitis when added to drinking water. The FDA found no human study by any route, so there is no evidence it helps wounds, skin, gut inflammation, nerve damage or stroke in humans, despite how it is promoted.
What are the side effects of KPV?
Nobody knows. The FDA found no human data on KPV by any route and could not assess its risk of immune reactions. Its adverse event database had no KPV reports through December 2025, but with no human studies, that does not show it is safe. KPV also has no official drug standard (USP monograph).
Sources
- U.S. Food and Drug Administration, 2026: FDA Briefing Document for KPV-Related Bulk Drug Substances (PCAC, July 23-24, 2026) (opens in a new tab)
- U.S. Food and Drug Administration, 2026: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (opens in a new tab)
Is KPV FDA-approved?
No. KPV is not approved for any use and is not in any FDA-approved drug. It was nominated for pharmacy compounding only as a cream or gel for the skin, not as an injection. In July 2026 FDA staff recommended against adding it to the list pharmacies may compound from, citing the lack of any human data; the advisory committee narrowly voted the other way. That vote is not binding. The FDA would have to publish a proposed rule first, and as of October 16, 2026 it had not.
Sources
- U.S. Food and Drug Administration, 2026: FDA Briefing Document for KPV-Related Bulk Drug Substances (PCAC, July 23-24, 2026) (opens in a new tab)
- U.S. Food and Drug Administration, 2026: July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (opens in a new tab)
- ABC News, 2026: FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next? (opens in a new tab)
What is the difference between BPC-157 and KPV?
They are unrelated molecules. KPV has 3 amino acids and comes from the hormone alpha-MSH; BPC-157 has 15 and is based on a protein in gastric juice. BPC-157 has five small human studies; KPV has none. The FDA reviewed both at the same July 2026 meeting, and its staff recommended against both. No study has tested them together.
Sources
Is KPV banned in sport?
KPV is not named on WADA’s 2026 Prohibited List, but that does not make it allowed. WADA’s S0 rule bans, at all times, any substance not covered elsewhere on the list that has no current approval by any government health authority for human use. Athletes should check with their anti-doping organization.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA Briefing Document for KPV-Related Bulk Drug Substances (PCAC, July 23-24, 2026)U.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What’s next?ABC News, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationGastroenterology, 2008 · Accessed Oct 16, 2026 (opens in a new tab)
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances (PCAC, July 23-24, 2026)U.S. Food and Drug Administration, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
- World Anti-Doping Code International Standard: Prohibited List 2026World Anti-Doping Agency, 2026 · Accessed Oct 16, 2026 (opens in a new tab)
Related compounds
Guides
Every medical and regulatory statement on this page links to a checkable source, listed above. Peptinote does arithmetic and education, not medical advice, and never sells or links to sellers of peptides.